ClinicalTrials.gg
CompletedNCT04073589Updated Dec 30, 2019

Efgartigimod Co-administered Subcutaneously With rHuPH20 in Healthy Subjects

A Phase 1 interventional study of ARGX-113 with rHuPH20 in Healthy Volunteers, sponsored by argenx. Completed at 1 site in Netherlands. Open to male participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-12-30.

Sponsored by argenx · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Male
01

Study summary

The aim of this trial is to investigate the pharmacodynamic (PD), pharmacokinetic (PK), safety, tolerability, and immunogenicity of efgartigimod co-administered with rHuPH20, and to measure the time to inject the full dose of investigational medicinal product (IMP) of different dose levels of efgartigimod co-administered with a fixed concentration of rHuPH20 by the subcutaneous (SC) route of administration in healthy adult male subjects.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is male, between 18 to 70 years of age
  2. Subject is healthy
  3. Subject has a (BMI) between 18 kg/m2 to 30 kg/m2
  4. Subject is willing and able to understand the purpose and risks of the trial and provide signed and dated ,
  5. Others as defined in the protocol

Exclusion criteria

Exclusion Criteria:

  1. Previous participation in clinical trials with efgartigimod and/or any products with rHuPH20.
  2. Known to IMP ingredients or history of a severe allergic or anaphylactic reaction to any drug as determined by the investigator.
  3. Known seropositivity or positive test at screening for an active viral infection with virus (HBV), virus (HCV), (HIV).
  4. Known immunological disorders.
  5. Known history or any symptom of clinically significant illness in the 6 months before IMP administration.
  6. Others as defined in the protocol
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Treatment A

    Single SC injection of Dose A

    Biological: ARGX-113 with rHuPH20

  • Experimental
    Treatment B

    Single SC injection of Dose B

    Biological: ARGX-113 with rHuPH20

  • Experimental
    Treatment C

    Single SC injection of Dose C

    Biological: ARGX-113 with rHuPH20

  • Experimental
    Treatment D

    Single SC injection of Dose D

    Biological: ARGX-113 with rHuPH20

Interventions

06

What researchers measure

Primary outcomes

  1. IgG levels of four different subcutaneous dose levels

    Time frame: Up to 11 weeks, from study start until the end of the study

Secondary outcomes

  1. Maximum serum concentrations (Cmax) of four different subcutaneous dose levels of efgartigimod co-administered with rHuPH20

    Time frame: Up to 11 weeks, from study start until the end of the study

  2. Time to reach maximum serum concentrations (Tmax) of four different subcutaneous dose levels of efgartigimod co-administered with rHuPH20

    Time frame: Up to 11 weeks, from study start until the end of the study

  3. Area Under The Curve (AUC) of four different subcutaneous dose levels of efgartigimod co-administered with rHuPH20

    Time frame: Up to 11 weeks, from study start until the end of the study

  4. Number of (serious) adverse events

    Time frame: Up to 11 weeks, from study start until the end of the study

  5. Level of anti-drug antibodies

    Time frame: Up to 11 weeks, from study start until the end of the study

  6. Time required to administer the different doses

    Time frame: Up to 11 weeks, from study start until the end of the study

07

Study locations

1 site
  • Investigator Site
    Groningen, Netherlands
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2019 to primary completion in Sep 2019, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2019
First posted
Aug 29, 2019
StartActual
Jul 17, 2019
Primary completionActual
Sep 26, 2019
CompletionActual
Sep 26, 2019
Last update
Dec 30, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04073589
Lead sponsor
argenx
Responsible party
Sponsor
First posted
Aug 29, 2019
Start date
Jul 17, 2019
Primary completion
Sep 26, 2019
Completion
Sep 26, 2019
Last update
Dec 30, 2019

Study contacts

Antonio Guglietta, MD
study director · argenx

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Efgartigimod alfa · Hyaluronidase (human recombinant)

Start the discussion